Recce Pharmaceuticals Secures Key China Patent for Synthetic Anti-Infectives

Key Highlights:

• Recce granted China patent for anti-infectives R327 and R529, extending IP to the world’s second-largest pharma market
• Patent covers broad applications, from bacterial and viral infections to innovative delivery methods
• R327 and R529 target critical unmet needs, including superbugs and antibiotic-resistant pathogens
• Recce’s growing global patent portfolio now spans Australia, Canada, Israel, Japan, and China
  
   

Recce Pharmaceuticals Ltd (ASX: RCE) has added a significant milestone to its intellectual property portfolio, securing a patent grant from the China National Intellectual Property Administration for its flagship anti-infectives, RECCE® 327 (R327) and RECCE® 529 (R529). This extension into China, home to the world’s second-largest pharmaceutical market, valued at an estimated US$4.09 billion for antibiotics alone, marks a pivotal step in Recce’s global strategy.

The newly accepted patent, part of Recce’s Family 4 series, provides broad protection for R327 and R529, covering their manufacturing processes, applications for treating bacterial and viral infections (including life-threatening conditions like sepsis, pneumonia, and SARS-CoV-2), and versatile delivery formats such as oral, injectable, inhaled, topical, and transdermal therapies. The patent’s scope also spans innovative formulations like aerosols, foams, and impregnated dressings, reflecting Recce’s ambition to tackle antibiotic-resistant superbugs across diverse clinical settings.

This development builds on Recce’s growing IP footprint, which includes patents granted in Australia, Canada, Israel, and Japan, with additional applications progressing under the Patent Cooperation Treaty (PCT). CEO James Graham emphasized the strategic value of this grant: “This patent will broaden our protection for Family 4 anti-infectives in a key global market. We’re grateful to the Chinese authorities for recognizing the unique capabilities of Recce’s anti-infectives, which we believe are well-positioned to address the urgent challenges of antimicrobial resistance.”

Recce’s innovative pipeline, including R327 for sepsis and drug-resistant bacterial infections, R435 for oral bacterial therapy, and R529 for viral infections, has garnered global attention. The World Health Organization has listed Recce’s anti-infectives on its priority development pipeline, and R327 has received the FDA’s coveted Qualified Infectious Disease Product (QIDP) designation, offering fast-track review and 10 years of market exclusivity upon approval.

While Recce’s stock (ASX: RCE) traded flat at $0.29 today, the company’s strategic IP expansion positions it well in the global fight against antibiotic-resistant pathogens. With China’s antibiotic market forecast to grow at a 5.7% CAGR through 2030, Recce’s entry into this key market could unlock substantial commercial opportunities in the years ahead.